TSHA - CIK 0001806310
Taysha Gene Therapies, Inc. (TSHA) reported net income of -$109.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
| Fiscal year | Net Income | Change |
|---|---|---|
| FY 2025 | -$109.00M | -22.1% |
| FY 2024 | -$89.30M | +20.0% |
| FY 2023 | -$111.57M | +32.8% |
| FY 2022 | -$166.01M | +4.9% |
| FY 2021 | -$174.52M | -190.8% |
| FY 2020 | -$60.01M | - |
Taysha Gene Therapies, Inc. (TSHA) reported net income of -$109.00M for fiscal year 2025, as filed in its audited annual report with the SEC.
Between fiscal 2020 and fiscal 2025, Taysha Gene Therapies, Inc.'s net income declined from -$60.01M to -$109.00M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.